Inhibrx, Inc. (NASDAQ:INBX) Sees Large Growth in Short Interest

Inhibrx, Inc. (NASDAQ:INBX) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,090,000 shares, an increase of 5.8% from the November 15th total of 1,030,000 shares. Based on an average daily trading volume, of 84,700 shares, the short-interest ratio is currently 12.9 days. Currently, 11.0% of the company’s stock are short sold.

Inhibrx Stock Down 0.4 %

NASDAQ INBX opened at $14.56 on Tuesday. The firm’s fifty day moving average price is $15.36 and its two-hundred day moving average price is $14.80. Inhibrx has a 1 year low of $10.80 and a 1 year high of $18.95.

Insider Activity

In related news, Director Jon Faiz Kayyem acquired 69,686 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $14.23 per share, with a total value of $991,631.78. Following the acquisition, the director now owns 51,093 shares in the company, valued at $727,053.39. This represents a -374.80 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.20% of the stock is owned by corporate insiders.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.